Table of Contents

---

[AASTROM BIOSCIENCES INC LETTERHEAD]                               EXHIBIT 99.1
P.O. Box 376 - Ann Arbor, Michigan 48106 - Ph: 734-930-5555 - Fax: 734-665-0485
Located at: Domino's Farms, Lobby L

FOR IMMEDIATE RELEASE

CONTACTS:   Kris M. Maly or Becky Anderson            Kevin McGrath
            Investor Relations Department             Cameron Associates
            Aastrom Biosciences, Inc.                 Phone:  (212) 245-4577
            Phone:  (734) 930-5777

                 WARREN CHAUNCE BOGARD, JR., PH.D. APPOINTED TO
                     AASTROM BIOSCIENCES' BOARD OF DIRECTORS

ANN ARBOR, MICHIGAN, FEBRUARY 4, 2005 -- Aastrom Biosciences, Inc. (NasdaqSC:
ASTM) announced today that Warren Chaunce Bogard, Jr., Ph.D. has been appointed
to the Company's Board of Directors. In his role as a member of the Board, Dr.
Bogard will serve on the Aastrom Compensation and Governance & Nominating
Committees. Dr. Bogard's appointment became effective February 2, 2005.

"Dr. Bogard brings Aastrom a wealth of experience in the development and
commercialization of medical products," said R. Douglas Armstrong, Ph.D., Chief
Executive Officer and Chairman of Aastrom. "He is a seasoned scientific and
business executive with more than 20 years of accomplishments in
biopharmaceutical and medical diagnostic management. His broad expertise will
complement the talents of his fellow directors, and contribute greatly to
Aastrom as it progresses in its transformation from a development company to a
company actively engaged in the commercialization of its products."

Dr. Bogard is the founder and President of Bogard & Associates, a consulting
firm dedicated to assisting emerging biotechnology and healthcare companies in
general management, strategic planning, business development and new product
marketing. Prior to this, for 6 years, he held several senior level positions in
new product marketing at Merck & Co., Inc. in which he was responsible for
developing and executing strategic plans for launching new classes of
pharmaceutical products into the U.S. market. For over 15 years, Dr. Bogard held
various technical and business management positions at Centocor, Inc., including
Senior Vice President & General Manager of Centocor Diagnostics, where he also
served as an officer of the Company. He has served as a member of the Board of
Directors for Tektagen, Inc., a privately held contract services organization,
and was also a member of the Board of Directors of The Pennsylvania
Biotechnology Association. Dr. Bogard received a Bachelor of Science degree in
Chemistry and a Ph.D. in Biochemistry from Purdue University.

ABOUT AASTROM BIOSCIENCES, INC.

Aastrom Biosciences, Inc. (NasdaqSC: ASTM) is developing treatments for the
repair of damaged human tissues and other medical disorders, or the generation
of normal human tissues, utilizing the Company's proprietary adult stem
cell-based products. Aastrom's strategic position in the tissue regeneration and
cell therapy sectors is enabled by its proprietary Tissue Repair Cells (TRCs), a
mix of bone marrow stem and progenitor cells, and the AastromReplicell(R)
System, an industry-unique automated cell production platform used to produce
cells for clinical use. Together TRCs and the AastromReplicell System provide a
foundation that the Company is leveraging to produce multiple Prescription Cell
Products (PCPs), several of which are now in the clinical stage in the U.S. and
EU. TRCs are the core component of the PCPs Aastrom is developing for bone
grafting, peripheral vascular disease, jaw bone reconstruction and spine fusion
markets. The Company has also developed the AastromReplicell System for
dendritic cell production for researchers and institutions developing vaccines
to treat cancer and infectious diseases, under its Cell Production Products
line.

                                                           Aastrom-Bogard to BOD
                                                                February 4, 2005
                                                                          Page 2

For more information, visit Aastrom's website at www.aastrom.com.

This document contains forward-looking statements, including without limitation,
statements regarding product development objectives, commercial introduction and
expansion goals,and market development plans, which involve certain risks and
uncertainties. The forward-looking statements are also identified through use of
the words "intended," and other words of similar meaning. Actual results may
differ significantly from the expectations contained in the forward-looking
statements. Among the factors that may result in differences are the results
obtained from clinical trial activities, regulatory approval requirements, and
the availability of resources. THESE AND OTHER SIGNIFICANT FACTORS ARE DISCUSSED
IN GREATER DETAIL IN AASTROM'S ANNUAL REPORT ON FORM-10K AND OTHER FILINGS WITH
THE SECURITIES AND EXCHANGE COMMISSION.

                                       ###